Breaking News
The dual-use robotics and standalone navigation platform will become part of the VELYS Enabling Technologies portfolio.
VELYS SPINE is intended for use in planning and instrumenting spinal fusion procedures in the cervical, thoracolumbar, and sacroiliac spine. Photo: PRNewswire/DePuy Synthes.
Michael Barbella, Managing Editor08.02.24
DePuy Synthes today launched a proprietary dual-use robotics and standalone navigation platform—VELYS Active Robotic-Assisted System (VELYS SPINE)—developed in collaboration with eCential Robotics. VELYS SPINE received U.S. Food and Drug Administration (FDA) 510(k) clearance and is intended for use in planning and instrumenting spinal fusion procedures in thecervical,thoracolumbarand sacroiliac spine.
This new spine technology was designed to help surgeons tackle their most complex challenges. The VELYS SPINE system is dual use, meaning it features both a standalone navigation and an active robotics platform that can enable surgeon flexibility in their approach and plans. Active robotics allows for surgical guidance tailored to surgeon preference. The features and capabilities of active robotics technology are set to establish a new standard in spine surgical care.
“We are shaping the next frontier of orthopaedic innovation with a relentless focus on digital advancements and excellence in the field of surgical robotics and navigation. Our dedication extends to enhancing patient care through significant strides in spine surgery," said Aldo Denti,* company group chair, DePuy Synthes. “This is a major step in growing our VELYS Portfolio and in our commitment to supporting spine surgeons and their patients with advanced tools.”
The VELYS SPINE system is designed to address the uniquely complex needs of spine surgeons. The system offers a customizable experience with pathology-specific workflows, aided by capabilities such as VELYS Adaptive Tracking Technology and VELYS Trajectory Assistance. It will be used with the DePuy Synthes core Spine portfolio of products, including the TriALTIS Spine System and Navigation Enabled Instruments, the SYMPHONY Occipito-Cervico-Thoracic (OCT) System, VIPER PRIME System and EXPEDIUM VERSE Systems.
“Today's landscape of enabling technologies features first-generation robotics systems that may face challenges in adapting to individual surgeon needs,” said Russell Powers,† worldwide president, Spine, DePuy Synthes. “We recognize the urgent need for innovative solutions that offer new ways to engage with enabling technologies, returning control to surgeon’s hands. We believe that the unique features and capabilities of active robotics technology will set a new standard in surgical care for spine patients everywhere.”
Starting today, the VELYS SPINE system will be displayed throughout the United States in the MedTech Innovation Experience mobile lab, with other technologies and products currently available in DePuy Synthes' spine portfolio.The MedTech Innovation Experience offers hands-on learning opportunities to surgeons, fellows, residents, and other healthcare professionals. Commercial availability is expected in the first half of 2025.
DePuy Synthes, the orthopedics company of Johnson &Johnson MedTech,provides a comprehensive orthopedics portfolio offering solutions in specialties such as joint reconstruction, trauma, extremities, craniomaxillofacial, spinal surgery, and sports medicine. In addition to the VELYS Digital Surgery portfolio, the solutions aim to advance patient care while delivering clinical and economic value to healthcare systems worldwide.
Johnson & Johnson MedTech drives breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopedics, vision, and interventional solutions, the company strives to provide healthcare treatments are smarter, less invasive, and more personalized.
* Aldo Denti is an employee of Medical Device Business Services Inc.
† Russell Powers is an employee of Medical Device Business Services Inc.
'; var curr = null, n = 0; function countChars(el) { var text = el.nodeValue || el.innerHTML; iterateText: for (var i = 0; i < text.length; i++) { ++n; if (n === insertIndex) { curr = el; break iterateText; } } ; return curr } var elems = elem.contents(); iterateNodes : for (var i = 0; i < elems.length; i++) { if (elems[i].childNodes.length) { for (var c = 0; c < elems[i].childNodes.length; c++) { /*if(elems[i].childNodes[c].length && NewContent==true) { break iterateNodes; } if(breakToad==true && elems[i].childNodes[c]=='
') { NewContent=true; }*/ if (countChars(elems[i].childNodes[c])) { break iterateNodes; breakToad = true; } } } } if (!$('.contentBody552161').hasClass('addedad')) { elem.find(curr).after($articleWithAd); $('.contentBody552161').addClass('addedad'); } } googletag.cmd.push(function() { var adSize = [[1, 1], [740, 150], [740, 200], [468, 60], [468, 90], [468, 100], [468, 120], [300, 250], [468, 60]]; if (mobileMode) { var adSize = [[1, 1], [300, 90], [300, 45], [300, 37], [300, 58], [300, 38], [300, 25], [300, 27], [300, 24], [300, 47], [300, 28], [300, 50], [300, 250], [266, 195], [290, 395], [300, 100], [300, 212], [300, 250], [300, 300], [300, 400], [300, 500], [300, 600], [300, 700], [300, 768], [300, 800], [300, 150], [300, 750]]; }mainContent1552161 = googletag.defineSlot('/56119504/odt_main-content-1', adSize, 'main-content-ad-552161-1').addService(googletag.pubads()); mainContent1552161.setTargeting("odt", ["breaking-news"]); googletag.enableServices(); }); googletag.cmd.push(function() { googletag.display('main-content-ad-552161-1'); }); $('#main-content-ad-552161-1').append("
"); checkDoubleClickIframeLoaded('odt', 'main-content-ad-552161-1'); });
